Oops! In the U.S Lilly shares drop as twitter posts insulin now free!

Status
Not open for further replies.
Amity Island

Amity Island

Well-Known Member
Relationship to Diabetes
Type 1
Oopps!

Eli Lilly’s stock dipped Friday morning after someone paid $8 to verify a Twitter handle resembling that of the pharmaceutical giant and posted: “We are excited to announce insulin is free now.”

The prank appears to have served to highlight this harsh reality, prompting backlash from people who use Twitter. Other insulin manufacturers, Sanofi and Novo Nordisk, also saw their stocks take a dip.

www.huffingtonpost.co.uk

Eli Lilly Stock Dips After Verified Twitter Imposter Says Insulin Is Free

Whoops!
www.huffingtonpost.co.uk www.huffingtonpost.co.uk
 
Just seen this in the news myself and find the whole Twitter situation fascinating from the perspective of someone who is very wary of such platforms. I think it is amazing that stocks can dip so massively from something so trivial in some senses and so hugely important in others. Whoever spent that $8 deserves a big pat on the back for throwing a flood light on the problem of the price of insulin in the USA. Well done that person!
 
The Chiqita one made me laugh 🙂

Hope twitter survives Musk.

On Lilly - anyway, Humalog is going to look pretty insiginificant compared to the vast rivers of gold they'll see from tirzepatide/Mounjaro ...
 
Eddy Edson said:
On Lilly - anyway, Humalog is going to look pretty insiginificant compared to the vast rivers of gold they'll see from tirzepatide/Mounjaro
Click to expand...

Alas it still won’t make them reverse the, frankly obscene, price rises for a drug whose formula is completely unchanged since it was more like $25 a vial rather than several hundred USD. :(
 
everydayupsanddowns said:
Alas it still won’t make them reverse the, frankly obscene, price rises for a drug whose formula is completely unchanged since it was more like $25 a vial rather than several hundred USD. :(
Click to expand...
And the fact of the matter is that it is almost 10x more expensive in the US than most other places in the world, so Musk's supportive comment of Eli Lilly is not correct.
 
everydayupsanddowns said:
Alas it still won’t make them reverse the, frankly obscene, price rises for a drug whose formula is completely unchanged since it was more like $25 a vial rather than several hundred USD. :(
Click to expand...
The US market structures are designed to allow pharma, insurers, PBM's, wholesalers to all get their snouts deeply & securely enguzzled in the trough at the expense of individuals and govt. It is a nexus of evil and it will not last (I think, hopefully).

I looked at Lilly's numbers because I'm a nerd and I was a bit surprised at the make-up. The biggest product by a long shot is Trulicity, which along with Jardiance is still showing big growth. Also, Mounjaro/tirzepatide has exploded out of the gate and looks set to overtake everything, barring production screw-ups etc. On the other hand, all of the insulin products show declining or at best flat revenue, notably Humalog/Lispro.

Not very relevant, but I guess if you want to punish Lilly for its evil ways insulin isn't necessrily the best thing to target.
 
Last edited:
Eddy Edson said:
Not very relevant, but I guess if you want to punish Lilly for its evil ways insulin isn't necessrily the best thing to target.
Click to expand...
Though on the other hand, the cost of insulin is implicated in killing people, who find it so unaffordable they limit their use. :(
 
everydayupsanddowns said:
Though on the other hand, the cost of insulin is implicated in killing people, who find it so unaffordable they limit their use. :(
Click to expand...
Lilly would (actually, does) say that it's shown it cares about that by eg introducing its own Humalog generic, Lispro, for people without insurance, priced to the end-user at some fraction of Humalog's list price.

Of course this is a ploy to make themselves look less evil and I think pricing is still relatively high. But there are elements in the Lispro story which I think illustrate how it's a nexus of evil also involving the PBM's, insurers, wholesalers, not just Lilly.

For one thing: what has to be the case for it to make sense for Lilly to sell exactly the same product but branded, priced & merchandised differently depending on the insurance status of the end user? At face value, it's bizarre.
 
Status
Not open for further replies.
Back
Top